Ivonne Visit 1: A 33-Year-Old Woman With Multiple Sclerosis Presenting With Cognitive Symptoms

Title:

Ivonne Visit 1: A 33-Year-Old Woman With Multiple Sclerosis Presenting With Cognitive Symptoms

Topic: Neurology
Relevant Terms: Cognition In Multiple Sclerosis, Multiple Sclerosis
Primary Audience: This activity is targeted to Neurologists; Nurses; Physician Assistants; and others who specialize in the care of patients with MS.
Launch Date: 27-Oct-10
Credits: 0.5 AMA PRA Category 1 Credit
0.5 ANCC contact hour
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

Upon completion of the activity, participants should be able to:

  1. Determine which MS patients should undergo neuropsychological screening, and select appropriate assessment tools
  2. Discuss the role of neuroimaging in detecting neurodegeneration and cognitive dysfunction in MS
  3. Identify the impact on cognition and neuroprotection of early treatment with MS disease-modifying therapies

    Faculty

    Maria Pia Amato, MD
    Associate Professor of Neurological and Psychiatric Sciences
    Director, Multiple Sclerosis Centre
    University of Florence
    Florence, Italy
    George H. Kraft, MD, MS
    Alvord Professor of Multiple Sclerosis Research
    Department of Rehabilitation Medicine and Neurology
    University of Washington School of Medicine
    Director
    Western Multiple Sclerosis Clinical Center
    University of Washington Medical Center
    Seattle, Washington
    Amy Perrin Ross, APN, MSN, CNRN, MSCN
    Neurosciences Program Coordinator
    Department of Neurosciences
    Loyola University Health System
    Maywood, Illinois
    DIME Editor
    Rosalee Blumer, MA
    Scientific Director
    DIME
    Chicago, Illinois
     
    Target Audience
    This activity is targeted to nurses, physician assistants, neurologists, and others who specialize in the care of patients with MS.

    Activity Purpose
    The purpose of this educational activity is to increase competence in the assessment and management of neuropsychological impairment in patients with multiple sclerosis.

    Statement of Need
    Recent studies show that more than 50% of patients with multiple sclerosis (MS) may be cognitively impaired. Most studies on cognition and MS evaluate patients in later stages of the disease who have marked physical disability. Patients in the early stages of MS or clinically isolated syndrome, or patients with minimal physical disability and mild or so-called "benign" MS, are rarely screened. Until more effective neuroprotective agents become available, neuropsychological screening and cognitive rehabilitation will remain significant components of the comprehensive care of patients with MS. However, clinicians require more education about neuropsychological assessment and management of symptoms in patients with early disease so that cognitive issues can be addressed and treated before significant, irreversible damage occurs.

    Content Independence
    This CME/CE activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals. The content was developed independently by the contributing faculty and has undergone peer review by the chairperson. All materials appear with permission of the author(s). The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    Faculty Disclosures
    DIME requires that all persons who were in a position to control or influence the content of this CME/CE activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
     
    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers' prescribing information for these products. DIME requires the speaker to disclose that a product is not labeled for the use under discussion. The provider's documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME and INA/ANCC guidelines.

    Disclosures
    Maria Pia Amato, MD
    Sources of Funding for Research: Bayer Shering Pharma; Biogen-Dompé AG; Merck Serono S.A.; sanofi-aventis Group
    Consulting Agreements: Bayer Shering Pharma; Biogen-Dompé, AG; Merck Serono S.A.; sanofi-aventis Group
    Financial Interests/Stock Ownership: None
    Speakers' Bureau/Honorarium Agreements: Bayer Shering Pharma; Biogen-Dompé AG; Merck Serono S.A.; sanofi-aventis Group
    Discussion of Off-Label, Investigational, or Experimental Drug Use: None

    George H. Kraft, MD, MS
    Sources of Funding for Research: None
    Consulting Agreements: Acorda Therapeutics, Inc.;Bayer HealthCare Pharmaceuticals
    Speakers' Bureau/Honorarium Agreements: Acorda Therapeutics, Inc.;Bayer HealthCare Pharmaceuticals
    Financial Interests/Stock Ownership: None
    Discussion of Off-Label, Investigational, or Experimental Drug Use: None

    Amy Perrin Ross, APN, MSN, CNRN, MSCN
    Sources of Funding for Research: None
    Consulting Agreements: Acorda Therapeutics, Inc.; Bayer HealthCare Pharmaceuticals; EMD Serono, Inc; Genzyme Corporation; Novartis Pharmaceuticals Corp; Pfizer Inc; Teva Neuroscience, Inc.
    Speakers' Bureau/Honorarium Agreements:Acorda Therapeutics, Inc.;Bayer HealthCare Pharmaceuticals; EMD Serono, Inc.; Genzyme Corporation;Novartis Pharmaceuticals Corp; Pfizer Inc; Teva Neuroscience, Inc.
    Financial Interests/Stock Ownership: None
    Discussion of Off-Label, Investigational, or Experimental Drug Use: None

    DIME Editor
    Rosalee Blumer has nothing to disclose.

    Policy Disclosure
    In accordance with DIME policies, be advised that one or more presentations in this CME/CE activity might contain references to off-label or unapproved uses of drugs or devices. The use of these agents outside currently approved labeling is considered experimental, and the manufacturers' prescribing information for these products should be consulted.
     
    This CME/CE activity was planned and produced in accordance with Accreditation Council for Continuing Medical Education (ACCME) Essential Areas and Elements and in accordance with Illinois Nurses Association (INA) Policies and Educational Design Criteria.
     
    Continuing Medical Education
    DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    DIME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
     
    Continuing Nursing Education
    DIME is an approved provider of continuing nursing education by the Illinois Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
     
    Participants in this activity are eligible for up to 0.5 contact hours of continuing nursing education.

    Credit Determination
    A review committee has agreed that this material can be completed in 0.5 hours. This estimated study time in turn has determined the credit and contact hours being offered.
     
    Instructions for Receiving Credit
    By reviewing the course content and successfully completing the posttest and evaluation, clinicians are entitled to receive credit. The statement of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures
    • Participate in the activity
    • Complete the posttest and activity evaluation
    • Clinicians who successfully complete the posttest and evaluation will receive a CME certificate; successful completion is defined as a cumulative score of at least 60% correct
    • All other participants who successfully complete the posttest and evaluation will receive a certificate of participation

    Viewing Requirements
    PC
    Internet Explorer (v6 or greater), or Firefox
    Mac
    Safari


    This continuing medical education activity is sponsored by DIME.

                                                                     
     www.DIMedEd.org
     
    Commercial Support
    Supported by an educational grant from Bayer HealthCare Pharmaceuticals.


    ©2010 DIME 069-20334